NX-1607: lifting the Cbl-b brake to promote T cell activation through MAPK/ERK pathways
Journal for ImmunoTherapy of Cancer · 2025
DOI: 10.1136/jitc-2025-012979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Alex To und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, University of Hong Kong, Hong Kong, Hong Kong. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-cbl, Lymphocyte Activation, T-Lymphocytes, MAP Kinase Signaling System. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Casitas B lymphoma-b (Cbl-b) is an E3 ubiquitin ligase that serves as a critical brake on immune cell activations. It negatively fine-tunes immune responses through ubiquitination of signaling proteins. Cbl-b deficiency in mice leads to spontaneous tumor rejection and induces only mild, non-lethal autoimmunity, highlighting its potential as a promising immunotherapy target. NX-1607 is the first oral small molecule inhibitor of Cbl-b and it is currently in phase I clinical trial. A recent publication employed high-throughput drug combination screening to systematically elucidate the molecular pathways by which NX-1607 enhances T cell activation. The authors administered 81 well-characterized inhibitors to Jurkat T cells under CD3-stimulated and unstimulated conditions in the presence of NX-1607. Inhibitors of the MAPK/ERK pathway significantly attenuated NX-1607-enhanced T cell activation as indicated by CD69 markers. Proto-oncogene tyrosine-protein kinase Src (SRC) family kinase inhibitors also reduced both CD69 activation markers and the phosphorylation of PLCγ1 and HCLS1 which are upstream of MAPK/ERK pathways. These findings were validated in an immunocompetent B-cell lymphoma mouse model, where NX-1607 consistently upregulated PLCγ1 and ERK phosphorylation. Together, this work delineates a PLCγ1-MAPK/ERK axis through which Cbl-b inhibition unleashes T cell activation, providing critical insight for the development of NX-1607 based immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical Sciences, University of Hong Kong, Hong Kong, Hong Kong.
- School of Biomedical Sciences, University of Hong Kong, Hong Kong, Hong Kong rios@hku.hk.
- Centre for Translational Stem Cell Biology, University of Hong Kong, Hong Kong, Hong Kong.
Zitieren
APA
To, A., & Sugimura, R. (2025). NX-1607: lifting the Cbl-b brake to promote T cell activation through MAPK/ERK pathways. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-012979
Vancouver
To A, Sugimura R. NX-1607: lifting the Cbl-b brake to promote T cell activation through MAPK/ERK pathways. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-012979
BibTeX
@article{To2025,
author = {To, Alex and Sugimura, Ryohichi},
title = {NX-1607: lifting the Cbl-b brake to promote T cell activation through MAPK/ERK pathways},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
doi = {10.1136/jitc-2025-012979}
}
EUVIMED